Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.

摘要: Purpose: Several in vitro studies have shown that non-small cell lung cancer (NSCLC) lines are sensitive to apoptosis induction by the recombinant human (rh) tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death ligand, indicating rhTRAIL might become an attractive molecule for treatment of NSCLCs. To investigate therapeutic potential rhTRAIL, expression TRAIL and its receptors DR4 DR5 was evaluated tumors stage III NSCLC patients. Experimental Design: Before treatment, biopsies from locally advanced patients were obtained bronchoscopy. DR4, DR5, determined immunohistochemically 87 tumors. Patients randomized with 60 Gy radiotherapy or without carboplatin as radiosensitizer. Results: expressed 99%, 82%, 91% tumors, respectively. Seventeen percent samples only no DR5. In NSCLCs squamous differentiation, a typical staining pattern observed. Cells basal layer strongly positive, more mature cells less positive negative. An inverse observed TRAIL. Poorly differentiated areas showed strong intensity DR5-positive associated increased risk (odds ratio, 5.76; 95% confidence interval, 1.04–31.93; P = 0.045). Conclusions: The majority irresectable at least one two Therefore, these may provide target use new adjunct NSCLC.